0000950123-23-002178.txt : 20230214 0000950123-23-002178.hdr.sgml : 20230214 20230214072753 ACCESSION NUMBER: 0000950123-23-002178 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 EFFECTIVENESS DATE: 20230214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC CENTRAL INDEX KEY: 0001703031 IRS NUMBER: 813996001 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-18477 FILM NUMBER: 23622403 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162878 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 13F-HR 1 primary_doc.xml X0202 13F-HR LIVE 0001703031 XXXXXXXX 12-31-2022 12-31-2022 false Bain Capital Life Sciences Investors, LLC

200 Clarendon Street Boston MA 02116

13F HOLDINGS REPORT 028-18477 Y Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP, (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general parter of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iv) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general parnter of Bain Capital Life Sciences Fund III, L.P., which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP. The shares of common stock of Annexon, Inc. ("ANNX") included on the Information Table are as reported on Amendment No. 1 to the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP and BCLS I Investco, LP on February 14, 2023 and reflect the exercise of securities exercisable for shares of ANNX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding ANNX common stock following such exercise. As of December 31, 2022, such persons held an aggregate of 3,601,926 shares of ANNX common stock. The shares of common stock of Savara Inc. ("SVRA") included on the Information Table are as reported on Amendment No. 1 to the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on March 17, 2021 and reflect the exercise of securities exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise. As of December 31, 2022, such persons held an aggregate of 6,913,208 shares of SVRA common stock. The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP and BCLS II Equity Opportunities, LP on February 14, 2023 and reflect the exercise of securities exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise. As of December 31, 2022, such persons held an aggregate of 1,082,404 shares of SYRS common stock. The shares of common stock of X4 Pharmaceuticals, Inc. ("XFOR") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, BCLS II Investco, LP and BCLS I Investco, LP on February 14, 2023 and reflect the exercise of securities exercisable for shares of XFOR common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding XFOR common stock following such exercise. As of December 31, 2022, such persons held an aggregate of 11,590,336 shares of XFOR common stock. Adam Koppel 617-516-2000 /s/ Adam Koppel Boston MA 02-14-2023 11 33 894849 false 1 28-18476 Bain Capital Life Sciences Partners, LP 2 28-18478 Bain Capital Life Sciences Fund, L.P. 3 28-20270 BC SW, LP 4 28-20816 Bain Capital Life Sciences Investors II, LLC 5 28-20814 Bain Capital Life Sciences Fund II, L.P. 6 BCLS II Investco (GP), LLC 7 BCLS II Investco, LP 8 Bain Capital Life Sciences III General Partner, LLC 9 Bain Capital Life Sciences Fund III, L.P. 10 Bain Capital Life Sciences Opportunities III GP, LLC 11 Bain Capital Life Sciences Opportunities III, LP INFORMATION TABLE 2 20545.xml INFORMATION TABLE FOR FORM 13F 2SEVENTY BIO INC COMMON STOCK 901384107 13201 1408901 SH SOLE 1408901 0 0 ACADIA PHARMACEUTICALS INC COM 004225108 11166 701402 SH SOLE 701402 0 0 AEGLEA BIOTHERAPEUTICS INC COM 00773J103 2406 5347689 SH SOLE 5347689 0 0 ANNEXON INC COM 03589W102 25264 4886616 SH SOLE 4886616 0 0 APTINYX INC COM 03836N103 2537 8891758 SH SOLE 8891758 0 0 ARCUTIS BIOTHERAPEUTICS INC COM 03969K108 44400 3000000 SH SOLE 3000000 0 0 ATEA PHARMACEUTICALS INC COM 04683R106 11956 2485638 SH SOLE 2485638 0 0 C4 THERAPEUTICS INC COM STK 12529R107 9689 1642210 SH SOLE 1642210 0 0 CARA THERAPEUTICS INC COM 140755109 28955 2696030 SH SOLE 2696030 0 0 CRINETICS PHARMACEUTICALS IN COM 22663K107 42192 2305558 SH SOLE 2305558 0 0 CTI BIOPHARMA CORP COM 12648L601 22702 3777308 SH SOLE 3777308 0 0 DYNAVAX TECHNOLOGIES CORP COM NEW 268158201 41656 3915000 SH SOLE 3915000 0 0 EQRX INC COM 26886C107 24609 10003573 SH SOLE 10003573 0 0 INVIVYD INC COM 00534A102 2906 1937207 SH SOLE 1937207 0 0 MARINUS PHARMACEUTICALS INC COM NEW 56854Q200 5696 1431058 SH SOLE 1431058 0 0 MERSANA THERAPEUTICS INC COM 59045L106 50769 8663673 SH SOLE 8663673 0 0 NATERA INC COM 632307104 56238 1400000 SH SOLE 1400000 0 0 NAUTILUS BIOTECHNOLOGY INC COM 63909J108 3600 2000000 SH SOLE 2000000 0 0 NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARES N62509109 90470 8300000 SH SOLE 8300000 0 0 NEWAMSTERDAM PHARMA COMPANY *W EXP 11/22/202 N62509117 86 100000 SH SOLE 100000 0 0 NURIX THERAPEUTICS INC COM 67080M103 20015 1822883 SH SOLE 1822883 0 0 NUVALENT INC COM 670703107 106531 3577267 SH SOLE 3577267 0 0 PHARVARIS N V COM N69605108 35782 3180601 SH SOLE 3180601 0 0 PROTAGONIST THERAPEUTICS INC COM 74366E102 25796 2364410 SH SOLE 2364410 0 0 RAPID MICRO BIOSYSTEMS INC CLASS A COM 75340L104 9531 8434560 SH SOLE 8434560 0 0 SAVARA INC COM 805111101 18015 11622598 SH SOLE 11622598 0 0 SOLID BIOSCIENCES INC COM NEW 83422E204 16842 3130422 SH SOLE 3130422 0 0 SPRINGWORKS THERAPEUTICS INC COM 85205L107 125662 4831307 SH SOLE 4831307 0 0 SYROS PHARMACEUTICALS INC COM NEW 87184Q206 7628 2124694 SH SOLE 2124694 0 0 TANGO THERAPEUTICS INC COM 87583X109 13933 1921790 SH SOLE 1921790 0 0 THIRD HARMONIC BIO INC COM 88427A107 4952 1151657 SH SOLE 1151657 0 0 X4 PHARMACEUTICALS INC COM 98420X103 12117 12202510 SH SOLE 12202510 0 0 XILIO THERAPEUTICS INC COM 98422T100 7547 2805413 SH SOLE 2805413 0 0